What is the correct use of durvalumab (durvalumab)? How can patients use it correctly according to doctor's recommendations?

Durvalumab is an immune checkpoint inhibitor, a PD-L1 antibody drug, mainly used to treat certain types of cancer, especially non-small cell lung cancer and bladder cancer. It enables the immune system to recognize and attack cancer cells by suppressing inhibitory signals between tumor cells and immune cells. The correct use of durvalumab is crucial to the therapeutic effect, and patients need to follow the doctor's instructions to ensure the effectiveness and safety of the drug.

1. How to use

Durvalumab is usually administered as an intravenous injection. The amount of drug per injection and the frequency of administration are usually determined by the doctor based on the patient's condition and weight. Standard dosing is usually 1,500 mg per injection every two weeks, which means patients will need to go to the hospital for an intravenous infusion every two weeks.

During treatment, doctors will adjust the dosing frequency or dosage based on the patient's tolerance, treatment response, and possible side effects. Cycles of treatment may last several months or longer until the disease stabilizes or criteria for discontinuation of treatment are met.

2. Notes

Patients should follow the following precautions when using durvalumab:

Anaphylaxis: Durvalumab may cause an allergic reaction, especially soon after injection. If patients develop allergic symptoms such as shortness of breath, swelling of the face or throat, rash, itching, etc., they should seek medical attention immediately.

Immune-related adverse reactions: As an immunotherapy, durvalumab may cause an overactive immune system, leading to an inflammatory response. Common adverse reactions include pneumonia, hepatitis, colitis, etc. If you have persistent cough, shortness of breath, diarrhea, jaundice and other symptoms, you should report it to your doctor in time.

Drug Interactions: Durvalumab may interact with other drugs, especially other immunosuppressive drugs, antibiotics, or antiviral drugs. Therefore, patients should inform their doctor about all medications they are taking during treatment, including prescription drugs, over-the-counter drugs, and supplements.

During treatment with durvalumab, patients will need to undergo regular blood tests and imaging studies to monitor the effects and side effects of the drug. Common examination items include liver function, kidney function, lung function, blood routine, etc. The doctor will adjust the treatment plan based on the examination results to ensure the safety and effectiveness of the treatment process.

Reference materials:https://www.imfinzi.com/